Stifel Reiterates Buy Rating on Structure Therapeutics (GPCR)
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $50.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst commented, "GPCR ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


